Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT
Status:
Completed
Trial end date:
2019-01-09
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to test the efficacy of Lisdexamfetamine in Adults With
Attention Deficit Hyperactivity Disorder (ADHD) and Sluggish Cognitive Tempo (SCT). This is a
placebo controlled, cross-over clinical trial of oral Lisdexamfetamine Dimesylate 30-70mg/day
in adults with attention-deficit hyper-activity disorder and Sluggish Cognitive Tempo (ACT).
Patients will be assigned either LDX/Placebo for 10 weeks with a two week placebo washout
period.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health